We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

60 hedge funds and large institutions have $136M invested in Amicus Therapeutics in 2014 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more capital invested

Capital invested by funds: $71M → $136M (+$64.8M)

10% more call options, than puts

Call options by funds: $557K | Put options by funds: $505K

6% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 16

12% less funds holding

Funds holding: 6860 (-8)

35% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 23

Holders
60
Holders Change
-8
Holders Change %
-11.76%
% of All Funds
1.72%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
15
Increased
17
Reduced
16
Closed
23
Calls
$557K
Puts
$505K
Net Calls
+$52K
Net Calls Change
-$50K

FOLD Hedge Fund Activity: Q2 2014 in Review

60 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2014, worth a combined $136M — up 91% from $71M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of FOLD and 15 opened new positions — a net loss of 8 holders — while 16 trimmed existing stakes and 17 added.

The largest buyer was Perceptive Advisors, adding an estimated $26.7M. The largest seller was RS Investment Management, exiting entirely with an estimated $5.83M sold.

  • 60 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2014, down from 68 in Q1 2014.
  • Funds reported $136M of Amicus Therapeutics stock for Q2 2014, up 91% quarter-over-quarter.
  • 15 funds opened new Amicus Therapeutics positions in Q2 2014 and 23 closed out, a net change of -8 holders.
  • The largest Amicus Therapeutics buyer in Q2 2014 was Perceptive Advisors, an estimated $26.7M added.
  • The largest Amicus Therapeutics seller in Q2 2014 was RS Investment Management, an estimated $5.83M sold.

Based on aggregated 13F filings for Q2 2014.